Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin versus linezolid for complicated skin and soft tissue infections
ISRCTN63718248Phase 3Completed
- Sponsor
- United States Department of Health and Human Services
- Start
- Sep 2003
- Modality
- Small Molecules, Peptides
01
Overview
Phase 3, randomised, double-blind trial in skin and soft tissue infections (SSTIs) and Gram-positive bacterial infection comparing Dalbavancin with Linezolid (2 arms). Primary endpoints: Clinical response to therapy and Microbiological response to therapy. Started Sep 2003; status: completed.
02
Drugs
dalbavancinlinezolid
03
Conditions
skin and soft tissue infections (SSTIs)Gram-positive bacterial infection
Beyond the preview
Go deeper on ISRCTN63718248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63718248.